Tags

Type your tag names separated by a space and hit enter

An update on drugs for the treatment of menopausal symptoms.
Expert Opin Pharmacother 2015; 16(16):2437-47EO

Abstract

INTRODUCTION

Vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM) are recognized as the most frequent and bothersome symptoms associated with menopause. There are different treatments for both groups of symptoms, being necessary to individualize them.

AREAS COVERED

There are different therapies for VMS including hormonal treatments with estrogen, with and without progestins; the new alternative, tissue-selective estrogen complex (TSEC), tibolone, phytoestrogens and only progestins. Evidence also shows efficacy with selective serotonin reuptake inhibitors. Other nonhormonal alternatives exist as second-line treatments, all with not conclusive results. The GSM can be treated with nonhormonal treatments such as vaginal lubricants and moisturizers, other alternatives as vaginal laser needs to have more evidence. On the other hand, there is the possibility to use the hormonal treatments with systemic or local estrogen, which are the most effective treatment, the TSEC and the newest selective estrogen receptor modulator (SERM), ospemifene. Therapies with testosterone and dehydroepiandrosterone (DHEA) are still under study. The GSM can be treated with nonhormonal treatments such as vaginal lubricants and moisturizers, and other alternatives as vaginal laser need to have more evidence. On the other hand, there is the possibility to use the hormonal treatments with systemic or local estrogen, which are the most effective treatment, the TSEC and the newest SERM, ospemifene. Therapies with testosterone and DHEA are still under study.

EXPERT OPINION

The increasing numbers of therapies for menopausal symptoms open up new options, but we must individualize treatments. New possibilities arise in patients who did not have them and which can improve compliance and is also important to design strategies using combined or sequential treatments.

Authors+Show Affiliations

a Institute Palacios of Women's Health , Madrid, Spain +34 9 15 78 05 17 ; +34 9 14 31 99 51 ; ipalacios@institutopalacios.com.a Institute Palacios of Women's Health , Madrid, Spain +34 9 15 78 05 17 ; +34 9 14 31 99 51 ; ipalacios@institutopalacios.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26395223

Citation

Palacios, Santiago, and Andrea Mejias. "An Update On Drugs for the Treatment of Menopausal Symptoms." Expert Opinion On Pharmacotherapy, vol. 16, no. 16, 2015, pp. 2437-47.
Palacios S, Mejias A. An update on drugs for the treatment of menopausal symptoms. Expert Opin Pharmacother. 2015;16(16):2437-47.
Palacios, S., & Mejias, A. (2015). An update on drugs for the treatment of menopausal symptoms. Expert Opinion On Pharmacotherapy, 16(16), pp. 2437-47. doi:10.1517/14656566.2015.1085508.
Palacios S, Mejias A. An Update On Drugs for the Treatment of Menopausal Symptoms. Expert Opin Pharmacother. 2015;16(16):2437-47. PubMed PMID: 26395223.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An update on drugs for the treatment of menopausal symptoms. AU - Palacios,Santiago, AU - Mejias,Andrea, Y1 - 2015/09/22/ PY - 2015/9/24/entrez PY - 2015/9/24/pubmed PY - 2016/3/15/medline KW - genitourinary syndrome of menopause KW - hormonal therapy KW - selective estrogen receptor modulator KW - selective serotonin reuptake inhibitors KW - tissue-selective estrogen complex KW - vaginal laser KW - vasomotor symptoms SP - 2437 EP - 47 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 16 IS - 16 N2 - INTRODUCTION: Vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM) are recognized as the most frequent and bothersome symptoms associated with menopause. There are different treatments for both groups of symptoms, being necessary to individualize them. AREAS COVERED: There are different therapies for VMS including hormonal treatments with estrogen, with and without progestins; the new alternative, tissue-selective estrogen complex (TSEC), tibolone, phytoestrogens and only progestins. Evidence also shows efficacy with selective serotonin reuptake inhibitors. Other nonhormonal alternatives exist as second-line treatments, all with not conclusive results. The GSM can be treated with nonhormonal treatments such as vaginal lubricants and moisturizers, other alternatives as vaginal laser needs to have more evidence. On the other hand, there is the possibility to use the hormonal treatments with systemic or local estrogen, which are the most effective treatment, the TSEC and the newest selective estrogen receptor modulator (SERM), ospemifene. Therapies with testosterone and dehydroepiandrosterone (DHEA) are still under study. The GSM can be treated with nonhormonal treatments such as vaginal lubricants and moisturizers, and other alternatives as vaginal laser need to have more evidence. On the other hand, there is the possibility to use the hormonal treatments with systemic or local estrogen, which are the most effective treatment, the TSEC and the newest SERM, ospemifene. Therapies with testosterone and DHEA are still under study. EXPERT OPINION: The increasing numbers of therapies for menopausal symptoms open up new options, but we must individualize treatments. New possibilities arise in patients who did not have them and which can improve compliance and is also important to design strategies using combined or sequential treatments. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/26395223/An_update_on_drugs_for_the_treatment_of_menopausal_symptoms_ L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.2015.1085508 DB - PRIME DP - Unbound Medicine ER -